Brief: Ipsen To Seek Marketing Authorizations For Cabometyx Outside Of U.S., Japan

Ipsen SA

02/07/2024 06:08

July 2 (Reuters) - Ipsen SA  IPN.PA :
    * IPSEN EXPANDS COLLABORATION AND LICENSE AGREEMENT FOR
DEVELOPMENT OF CABOMETYX IN ADVANCED NEUROENDOCRINE TUMORS BASED
ON POSITIVE CABINET PHASE III TRIAL
    * DECISION ADDS TO EXISTING COLLABORATION AGREEMENT WITH
EXELIXIS,
PERMITTING IPSEN TO SEEK POTENTIAL MARKETING AUTHORIZATIONS FOR
CABOMETYX OUTSIDE OF U.S. AND JAPAN
    * IPSEN HAS ENGAGED WITH REGULATORY AUTHORITIES IN EUROPEAN
UNION
AND WILL SUBMIT A REGULATORY FILING ON BASIS OF THESE DATA

Source text for Workspace:  ID:nGNEbr0dfp 
Further company coverage:  IPN.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48587696600;))